NCT04903119 2026-02-13Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaUniversity of KentuckyPhase 1 Recruiting30 enrolled
NCT00788775 2018-11-15Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaDana-Farber Cancer InstitutePhase 2 Completed20 enrolled 14 charts